Jennifer Erdrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer Erdrich has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Bradley D. McDowell
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa
16 shared publications - Bradley T. Loeffler
University of Iowa 3 Holden Comprehensive Cancer Center Iowa City, Iowa
16 shared publications - Brian J. Smith
University of Iowa
16 shared publications - Elizabeth Verhage
University of Iowa 3 Holden Comprehensive Cancer Center Iowa City, Iowa
16 shared publications - Faith Elenwa
University of Iowa 3 Holden Comprehensive Cancer Center Iowa City, Iowa
16 shared publications - Jamie Sorensen
University of Iowa, USA
16 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 3. Unadjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary lung
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 3. Unadjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary lung
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 2. Unadjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary colorectal cancer
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 2. Unadjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary colorectal cancer
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 6. Multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary lung cancer
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 6. Multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary lung cancer
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 5. Multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary colorectal cancer
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 5. Multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary colorectal cancer
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 4. Multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary (female) breast cancer
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 4. Multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary (female) breast cancer
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Background:American Indian and Alaska Native (AIAN) people experience lower cancer survival than other racial/ethnic groups for several cancer sites. We explored predictors of cancer survival among AIAN people, with a specific focus on the potential impact of comorbidities. Methods:We analyzed the Surveillance, Epidemiology, and End Results–Medicare linked database. AIAN people diagnosed with breast (female only), lung, and colorectal cancers from 2000 to 2019, ages 66+ years at diagnosis, and with at least 1 year of Medicare coverage prior to diagnosis were included in the study. We used multivariable-adjusted Cox proportional hazards models to assess associations of comorbidity class, previously defined using latent class analysis, with overall and cancer-specific survival, adjusted for sociodemographic characteristics and area-based social measures. Results:The sample included 831 individuals with female breast cancer, 1,009 individuals with colorectal cancer, and 1,195 individuals with lung cancer. Comorbidity class was associated with 5-year hazard of death from any cause for patients with breast and colorectal cancers but not patients with lung cancer. Furthermore, we only observed associations of comorbidity class with 5-year cancer-specific death for lung cancer, in which the class associated with heart and vascular-related conditions experienced increased hazard of death. Conclusions:Higher comorbidity prevalence among AIAN people compared with other racial/ethnic groups did not contribute to observed disparities in cancer-specific survival; however, AIAN people with comorbid conditions may be more likely to experience death from any cause than those without these conditions. Impact:Differences in prevalence of comorbid conditions are unlikely to drive disparities in cancer-specific survival observed among AIAN people.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Background:American Indian and Alaska Native (AIAN) people experience lower cancer survival than other racial/ethnic groups for several cancer sites. We explored predictors of cancer survival among AIAN people, with a specific focus on the potential impact of comorbidities. Methods:We analyzed the Surveillance, Epidemiology, and End Results–Medicare linked database. AIAN people diagnosed with breast (female only), lung, and colorectal cancers from 2000 to 2019, ages 66+ years at diagnosis, and with at least 1 year of Medicare coverage prior to diagnosis were included in the study. We used multivariable-adjusted Cox proportional hazards models to assess associations of comorbidity class, previously defined using latent class analysis, with overall and cancer-specific survival, adjusted for sociodemographic characteristics and area-based social measures. Results:The sample included 831 individuals with female breast cancer, 1,009 individuals with colorectal cancer, and 1,195 individuals with lung cancer. Comorbidity class was associated with 5-year hazard of death from any cause for patients with breast and colorectal cancers but not patients with lung cancer. Furthermore, we only observed associations of comorbidity class with 5-year cancer-specific death for lung cancer, in which the class associated with heart and vascular-related conditions experienced increased hazard of death. Conclusions:Higher comorbidity prevalence among AIAN people compared with other racial/ethnic groups did not contribute to observed disparities in cancer-specific survival; however, AIAN people with comorbid conditions may be more likely to experience death from any cause than those without these conditions. Impact:Differences in prevalence of comorbid conditions are unlikely to drive disparities in cancer-specific survival observed among AIAN people.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 1. Unadjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary (female) breast cancer
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 1. Unadjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people diagnosed with first primary (female) breast cancer
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 7. Model fit statistics, comparing multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Supplementary Table 7. Model fit statistics, comparing multi-variable adjusted associations of demographic, clinical, and area-based measures with overall and cancer-specific survival among AIAN people.
- 26 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501142
Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis
PURPOSE: Antihormonal therapy, including tamoxifen or aromatase inhibitors, is central to the treatment of hormone receptor–positive breast cancers. A common adverse effect is genitourinary syndrome of menopause, which may be treated with vaginal estrogen. However, the safety of vaginal estrogen in breast cancer survivors remains controversial, leading to inconsistent clinical guidance and potential underuse. METHODS: We conducted a retrospective cohort study of 25,874 female patients with breast cancer age 65 years and older diagnosed between 2007 and 2017 using the SEER-Medicare Health Outcomes Survey (MHOS) registry. Patients who used vaginal estrogen after diagnosis (n = 1,053) were compared with nonusers (n = 24,821). Multivariable Cox proportional hazard models evaluated associations with overall and cause-specific mortality, adjusting for demographics, comorbidities, and oncologic factors. A secondary analysis modeled vaginal estrogen use as a time-dependent covariate. RESULTS: Vaginal estrogen use was associated with decreased overall mortality (adjusted hazard ratio [HR], 0.49; P < .01) and cause-specific mortality (adjusted HR, 0.31; P = .01). However, these associations were attenuated and no longer significant in time-dependent analysis. Among patients with hormone receptor–positive breast cancer, vaginal estrogen use was associated with reduced overall mortality (adjusted HR, 0.58; P = .02), although this lost significance in the time-dependent model. A nonsignificant reduction in cause-specific mortality was observed within this subgroup (adjusted HR, 0.45, P = .11). CONCLUSION: Vaginal estrogen use was not associated with worse overall survival or breast cancer–specific survival in this cohort SEER-MHOS cohort of patients older than 65 years. Loss of significance in time-dependent models suggests that initial associations may reflect immortal time or selection bias. These findings support growing evidence that local vaginal estrogen is not associated with adverse survival outcomes and may be considered for symptom management in appropriately selected patients.
- 26 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501142
Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis
PURPOSE: Antihormonal therapy, including tamoxifen or aromatase inhibitors, is central to the treatment of hormone receptor–positive breast cancers. A common adverse effect is genitourinary syndrome of menopause, which may be treated with vaginal estrogen. However, the safety of vaginal estrogen in breast cancer survivors remains controversial, leading to inconsistent clinical guidance and potential underuse. METHODS: We conducted a retrospective cohort study of 25,874 female patients with breast cancer age 65 years and older diagnosed between 2007 and 2017 using the SEER-Medicare Health Outcomes Survey (MHOS) registry. Patients who used vaginal estrogen after diagnosis (n = 1,053) were compared with nonusers (n = 24,821). Multivariable Cox proportional hazard models evaluated associations with overall and cause-specific mortality, adjusting for demographics, comorbidities, and oncologic factors. A secondary analysis modeled vaginal estrogen use as a time-dependent covariate. RESULTS: Vaginal estrogen use was associated with decreased overall mortality (adjusted hazard ratio [HR], 0.49; P < .01) and cause-specific mortality (adjusted HR, 0.31; P = .01). However, these associations were attenuated and no longer significant in time-dependent analysis. Among patients with hormone receptor–positive breast cancer, vaginal estrogen use was associated with reduced overall mortality (adjusted HR, 0.58; P = .02), although this lost significance in the time-dependent model. A nonsignificant reduction in cause-specific mortality was observed within this subgroup (adjusted HR, 0.45, P = .11). CONCLUSION: Vaginal estrogen use was not associated with worse overall survival or breast cancer–specific survival in this cohort SEER-MHOS cohort of patients older than 65 years. Loss of significance in time-dependent models suggests that initial associations may reflect immortal time or selection bias. These findings support growing evidence that local vaginal estrogen is not associated with adverse survival outcomes and may be considered for symptom management in appropriately selected patients.
- 24 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (8) , OF1-OF12
Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Background: American Indian and Alaska Native (AIAN) people experience lower cancer survival than other racial/ethnic groups for several cancer sites. We explored predictors of cancer survival among AIAN people, with a specific focus on the potential impact of comorbidities. Methods: We analyzed the Surveillance, Epidemiology, and End Results–Medicare linked database. AIAN people diagnosed with breast (female only), lung, and colorectal cancers from 2000 to 2019, ages 66+ years at diagnosis, and with at least 1 year of Medicare coverage prior to diagnosis were included in the study. We used multivariable-adjusted Cox proportional hazards models to assess associations of comorbidity class, previously defined using latent class analysis, with overall and cancer-specific survival, adjusted for sociodemographic characteristics and area-based social measures. Results: The sample included 831 individuals with female breast cancer, 1,009 individuals with colorectal cancer, and 1,195 individuals with lung cancer. Comorbidity class was associated with 5-year hazard of death from any cause for patients with breast and colorectal cancers but not patients with lung cancer. Furthermore, we only observed associations of comorbidity class with 5-year cancer-specific death for lung cancer, in which the class associated with heart and vascular-related conditions experienced increased hazard of death. Conclusions: Higher comorbidity prevalence among AIAN people compared with other racial/ethnic groups did not contribute to observed disparities in cancer-specific survival; however, AIAN people with comorbid conditions may be more likely to experience death from any cause than those without these conditions. Impact: Differences in prevalence of comorbid conditions are unlikely to drive disparities in cancer-specific survival observed among AIAN people.
- 24 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (8) , OF1-OF12
Impact of Comorbidities on Survival among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results–Medicare Study
Background: American Indian and Alaska Native (AIAN) people experience lower cancer survival than other racial/ethnic groups for several cancer sites. We explored predictors of cancer survival among AIAN people, with a specific focus on the potential impact of comorbidities. Methods: We analyzed the Surveillance, Epidemiology, and End Results–Medicare linked database. AIAN people diagnosed with breast (female only), lung, and colorectal cancers from 2000 to 2019, ages 66+ years at diagnosis, and with at least 1 year of Medicare coverage prior to diagnosis were included in the study. We used multivariable-adjusted Cox proportional hazards models to assess associations of comorbidity class, previously defined using latent class analysis, with overall and cancer-specific survival, adjusted for sociodemographic characteristics and area-based social measures. Results: The sample included 831 individuals with female breast cancer, 1,009 individuals with colorectal cancer, and 1,195 individuals with lung cancer. Comorbidity class was associated with 5-year hazard of death from any cause for patients with breast and colorectal cancers but not patients with lung cancer. Furthermore, we only observed associations of comorbidity class with 5-year cancer-specific death for lung cancer, in which the class associated with heart and vascular-related conditions experienced increased hazard of death. Conclusions: Higher comorbidity prevalence among AIAN people compared with other racial/ethnic groups did not contribute to observed disparities in cancer-specific survival; however, AIAN people with comorbid conditions may be more likely to experience death from any cause than those without these conditions. Impact: Differences in prevalence of comorbid conditions are unlikely to drive disparities in cancer-specific survival observed among AIAN people.